伊利替康联合5-Fu治疗晚期胃癌疗效观察

Effect Observation of Irinotecan and 5-Fu Regimen in the Treatment of Advanced Gastric Cancer

目的观察伊利替康联合5-Fu/LV方案治疗晚期胃癌的临床疗效和不良反应。方法 11例晚期胃癌患者,采用化疗方案：伊利替康140mg/m^2持续静脉滴60-90min,d1,甲酰四氢叶酸200mg/m^2持续静脉滴入2h,d1,5-FU400mg/m^2静脉推注,d1,5-FU1200mg/m^2,持续静脉滴注46h,14d为1个周期,连用4个周期。评价疗效。结果 11例患者均可评价疗效和不良反应。获得CR0例,占0%;PR5例,占45.4%,SD4例,占36.4%;PD2例,占18.2%;有效率为45.4%（5/11）。不良反应主要为骨髓抑制和迟发性腹泻。结论对于晚期胃癌患者,伊利替康联合5-Fu/LV是一种安全有效、不良反应可以耐受的治疗方法,值得临床进一步研究应用。

Objective To evaluate the clinical efficacy and adverse reactions of Irinotecan and 5-Fu/LV regimen in the treatment of advanced gastric cancer.Methods 11 cases of patients with advanced gastric carcinoma were given the chemotherapy：Irinotecan 140 mg/m ^2 iv drip for 30 -90 minutes,d l,Leucovorin 200 mg/m ^2 iv drip 2 hours,d 1,5-Fu 400 mg/m^ 2 iv d 1,5-Fu 1 200 mg/m^ 2 iv drip for 46 hours,and 14 days were as an cycle.The efficacy was evaluated after every 4 cycles.Results The efficacy and adverse reactions of all of 11 cases could be evaluated.CR 0 case,accounting for 0%;PR5 cases,accounting for 45.4%,SD 4 cases,accounting for 36.4%;PD 2 cases,accounting for 18.2%.The totally effective rate was 45.4%.Conclusion Irinotecan and 5-Fu/LV regimen is effective and well tolerable in the treatment of advanced gastric cancer,and it is worth to be used and researched widely.